Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Capitalistaon May 20, 2021 3:49pm
205 Views
Post# 33242022

RE:RE:RE:15$ US Target reiterated today as well

RE:RE:RE:15$ US Target reiterated today as wellI'm with Actuarial on this one.  One-year survival for PDAC under all existing treatments is around 28%.  The ASCO abstract (written before all results were in) stated that disease control was achieved in 33% of patients.  Not sure how long their period of observation was in this study, but 33% is a "modest" improvement over 28%.  

I'm not bashing - again, I'm very long on ONC. But they're at the stage where they're trying to find where it works and where it doesn't.  Sometimes it'll show dramatic improvements over existing treatments, sometimes it won't do better than existing treatments, and sometimes you'll only see modest improvements. 
<< Previous
Bullboard Posts
Next >>